Rein Therapeutics's total assets for Q4 2024 were $62.19M, a decrease of -40.33% from the previous quarter. RNTX total liabilities were $7.80M for the fiscal quarter, a -85.56% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.